The invention relates to compounds of general formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ri is selected from an SCN— group or is an RCONH— group; in particular, where Ri=RCONH, R is selected from an aromatic benzene ring substituted with an SCN— group in the ortho, meta or para position, according to the following formula: SCN— or R is a C1-C4 alkyl chain, substituted with an SCN— group; n can be equal to 0 or else 1. The invention also relates to the use of such compounds for the treatment of osteoporosis and in general of bone pathologies characterised by a progressive loss of bone mass, for example rheumatoid arthritis, hyperparathyroidism or bone tumour metastases

##STR00001##

Methods for the safe administration of imidazole or imidazolium compounds such as zoledronic acid, and conditions that may be treated by these methods, are described herein.

The invention relates to a marking precursor incorporating a chelator or fluorination group for radiolabelling with 44Sc, 47Sc, 55Co, 62Cu, 64Cu, 67Cu, 66Ga, 67Ga, 68Ga, 89Zr, 86Y, 90Y, 90Nb, 99mTc, 111ln, 135Sm, 140Pr, 159Gd, 149Tb, 160Tb, 161Tb, 165Er, 166Dy, 166Ho, 175Yb, 177Lu, 186Re, 188Re, 213Bi and 225Ac or with 18F, 131I or 211At, and one or two biological targeting vectors which are coupled to the chelator or fluorinating group via one or more squaric acid groups.

Described herein are bisphosphonate oxazolidinone compounds, and conjugates and pharmaceutical formulations thereof, that can include a bisphosphonate and an oxazolidinone (or an oxazolidinone antimicrobial or antibiotic agent, substituent or derivative thereof), where the oxazolidinone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate oxazolidinone compounds, conjugates and pharmaceutical formulations thereof. Also provided herein are methods of use of the compounds, conjugates and formulations for treating a bone disease or for use in preparing a formulation for the treatment a bone disease.

The present invention relates to EP4 agonist-bisphosphonate conjugates or related compounds and uses thereof. Said conjugates or related compounds may be used to provide delivery of an EP4 agonist or related compound to a desired site of action, such as a bone. Bisphosphonate moieties, linked to the EP4 agonists via amide linkers, have been implicated in the inhibition of bone resorption and bone targeting.

The present disclosure relates to a composition that includes a sequestering material capable of binding a target material, where the sequestering material includes a first component that includes at least one of a functional group, a molecule, an oligomer, or a polymer, and the target material includes at least one of an element, a chemical, and/or a compound. In some embodiments of the present disclosure, the element may include at least one element from at least one of Rows 4, 5, 6, and 7 of the Periodic Table and/or an inner transition metal.

Described herein are compositions including a silanol compound that is suitably synthesized, stored, and coated from an aqueous solution. Once coated and cured on a suitable surface, the aqueous silanol compositions result in cleanable and abrasion resistant surfaces, such as dry-erase surfaces that release permanent marker by rubbing with a dry cloth or towel. Also disclosed herein are methods of making the silanol compounds, methods of making cleanable substrates, and cleanable substrates suitably formed using the disclosed methods.

The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

The present invention relates to conjugate compounds and methods of making and using same.